Thought Leadership

Latest Report


PD(L)anner - December 2021

In this special report, we provide you with the latest Evaluate Vantage update on clinical and regulatory developments in the PD-(L)1 inhibitor space. Among other issues, we explore how the latest approvals could affect anti-PD-(L)1 latecomers. Download the PD(L)anner - December 2021 for analyses and insights that draw on the latest clinical…

Report library


ASH 2022 Conference Round Up

This article pack, produced by Evaluate Vantage’s team of award-winning journalists, presents expert analysis and insights on data recently presented at the 63rd annual…


Infographic: Evaluate Vantage 2022 Preview

Leading up to the publication of the Evaluate Vantage 2022 Preview, we created this Infographic to provide a snapshot of the products and companies that are driving top…


Evaluate Vantage 2022 Preview Report

Covid-19 will still be a front-page story in 2022, keeping the biopharma sector in the spotlight. The attention will bring some benefits, largely in the shape of broad…


Biopharma Quarterly Round Up (Q3 2021)

This article pack, produced by the editorial team at Evaluate Vantage, explores the key developments and decisions that are impacting the biopharma landscape. Access…